Cargando…
Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies against Delta and Omicron in Mice
As existing vaccines fail to completely prevent COVID-19 infections or community transmission, there is an unmet need for vaccines that can better combat SARS-CoV-2 variants of concern (VOC). We previously developed highly thermo-tolerant monomeric and trimeric receptor-binding domain derivatives th...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031315/ https://www.ncbi.nlm.nih.gov/pubmed/35458530 http://dx.doi.org/10.3390/v14040800 |
_version_ | 1784692360515420160 |
---|---|
author | Jansen van Vuren, Petrus McAuley, Alexander J. Kuiper, Michael J. Singanallur, Nagendrakumar Balasubramanian Bruce, Matthew P. Riddell, Shane Goldie, Sarah Mangalaganesh, Shruthi Chahal, Simran Drew, Trevor W. Blasdell, Kim R. Tachedjian, Mary Caly, Leon Druce, Julian D. Ahmed, Shahbaz Khan, Mohammad Suhail Malladi, Sameer Kumar Singh, Randhir Pandey, Suman Varadarajan, Raghavan Vasan, Seshadri S. |
author_facet | Jansen van Vuren, Petrus McAuley, Alexander J. Kuiper, Michael J. Singanallur, Nagendrakumar Balasubramanian Bruce, Matthew P. Riddell, Shane Goldie, Sarah Mangalaganesh, Shruthi Chahal, Simran Drew, Trevor W. Blasdell, Kim R. Tachedjian, Mary Caly, Leon Druce, Julian D. Ahmed, Shahbaz Khan, Mohammad Suhail Malladi, Sameer Kumar Singh, Randhir Pandey, Suman Varadarajan, Raghavan Vasan, Seshadri S. |
author_sort | Jansen van Vuren, Petrus |
collection | PubMed |
description | As existing vaccines fail to completely prevent COVID-19 infections or community transmission, there is an unmet need for vaccines that can better combat SARS-CoV-2 variants of concern (VOC). We previously developed highly thermo-tolerant monomeric and trimeric receptor-binding domain derivatives that can withstand 100 °C for 90 min and 37 °C for four weeks and help eliminate cold-chain requirements. We show that mice immunised with these vaccine formulations elicit high titres of antibodies that neutralise SARS-CoV-2 variants VIC31 (with Spike: D614G mutation), Delta and Omicron (BA.1.1) VOC. Compared to VIC31, there was an average 14.4-fold reduction in neutralisation against BA.1.1 for the three monomeric antigen-adjuvant combinations and a 16.5-fold reduction for the three trimeric antigen-adjuvant combinations; the corresponding values against Delta were 2.5 and 3.0. Our findings suggest that monomeric formulations are suitable for upcoming Phase I human clinical trials and that there is potential for increasing the efficacy with vaccine matching to improve the responses against emerging variants. These findings are consistent with in silico modelling and AlphaFold predictions, which show that, while oligomeric presentation can be generally beneficial, it can make important epitopes inaccessible and also carries the risk of eliciting unwanted antibodies against the oligomerisation domain. |
format | Online Article Text |
id | pubmed-9031315 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90313152022-04-23 Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies against Delta and Omicron in Mice Jansen van Vuren, Petrus McAuley, Alexander J. Kuiper, Michael J. Singanallur, Nagendrakumar Balasubramanian Bruce, Matthew P. Riddell, Shane Goldie, Sarah Mangalaganesh, Shruthi Chahal, Simran Drew, Trevor W. Blasdell, Kim R. Tachedjian, Mary Caly, Leon Druce, Julian D. Ahmed, Shahbaz Khan, Mohammad Suhail Malladi, Sameer Kumar Singh, Randhir Pandey, Suman Varadarajan, Raghavan Vasan, Seshadri S. Viruses Article As existing vaccines fail to completely prevent COVID-19 infections or community transmission, there is an unmet need for vaccines that can better combat SARS-CoV-2 variants of concern (VOC). We previously developed highly thermo-tolerant monomeric and trimeric receptor-binding domain derivatives that can withstand 100 °C for 90 min and 37 °C for four weeks and help eliminate cold-chain requirements. We show that mice immunised with these vaccine formulations elicit high titres of antibodies that neutralise SARS-CoV-2 variants VIC31 (with Spike: D614G mutation), Delta and Omicron (BA.1.1) VOC. Compared to VIC31, there was an average 14.4-fold reduction in neutralisation against BA.1.1 for the three monomeric antigen-adjuvant combinations and a 16.5-fold reduction for the three trimeric antigen-adjuvant combinations; the corresponding values against Delta were 2.5 and 3.0. Our findings suggest that monomeric formulations are suitable for upcoming Phase I human clinical trials and that there is potential for increasing the efficacy with vaccine matching to improve the responses against emerging variants. These findings are consistent with in silico modelling and AlphaFold predictions, which show that, while oligomeric presentation can be generally beneficial, it can make important epitopes inaccessible and also carries the risk of eliciting unwanted antibodies against the oligomerisation domain. MDPI 2022-04-13 /pmc/articles/PMC9031315/ /pubmed/35458530 http://dx.doi.org/10.3390/v14040800 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Jansen van Vuren, Petrus McAuley, Alexander J. Kuiper, Michael J. Singanallur, Nagendrakumar Balasubramanian Bruce, Matthew P. Riddell, Shane Goldie, Sarah Mangalaganesh, Shruthi Chahal, Simran Drew, Trevor W. Blasdell, Kim R. Tachedjian, Mary Caly, Leon Druce, Julian D. Ahmed, Shahbaz Khan, Mohammad Suhail Malladi, Sameer Kumar Singh, Randhir Pandey, Suman Varadarajan, Raghavan Vasan, Seshadri S. Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies against Delta and Omicron in Mice |
title | Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies against Delta and Omicron in Mice |
title_full | Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies against Delta and Omicron in Mice |
title_fullStr | Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies against Delta and Omicron in Mice |
title_full_unstemmed | Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies against Delta and Omicron in Mice |
title_short | Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies against Delta and Omicron in Mice |
title_sort | highly thermotolerant sars-cov-2 vaccine elicits neutralising antibodies against delta and omicron in mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031315/ https://www.ncbi.nlm.nih.gov/pubmed/35458530 http://dx.doi.org/10.3390/v14040800 |
work_keys_str_mv | AT jansenvanvurenpetrus highlythermotolerantsarscov2vaccineelicitsneutralisingantibodiesagainstdeltaandomicroninmice AT mcauleyalexanderj highlythermotolerantsarscov2vaccineelicitsneutralisingantibodiesagainstdeltaandomicroninmice AT kuipermichaelj highlythermotolerantsarscov2vaccineelicitsneutralisingantibodiesagainstdeltaandomicroninmice AT singanallurnagendrakumarbalasubramanian highlythermotolerantsarscov2vaccineelicitsneutralisingantibodiesagainstdeltaandomicroninmice AT brucematthewp highlythermotolerantsarscov2vaccineelicitsneutralisingantibodiesagainstdeltaandomicroninmice AT riddellshane highlythermotolerantsarscov2vaccineelicitsneutralisingantibodiesagainstdeltaandomicroninmice AT goldiesarah highlythermotolerantsarscov2vaccineelicitsneutralisingantibodiesagainstdeltaandomicroninmice AT mangalaganeshshruthi highlythermotolerantsarscov2vaccineelicitsneutralisingantibodiesagainstdeltaandomicroninmice AT chahalsimran highlythermotolerantsarscov2vaccineelicitsneutralisingantibodiesagainstdeltaandomicroninmice AT drewtrevorw highlythermotolerantsarscov2vaccineelicitsneutralisingantibodiesagainstdeltaandomicroninmice AT blasdellkimr highlythermotolerantsarscov2vaccineelicitsneutralisingantibodiesagainstdeltaandomicroninmice AT tachedjianmary highlythermotolerantsarscov2vaccineelicitsneutralisingantibodiesagainstdeltaandomicroninmice AT calyleon highlythermotolerantsarscov2vaccineelicitsneutralisingantibodiesagainstdeltaandomicroninmice AT drucejuliand highlythermotolerantsarscov2vaccineelicitsneutralisingantibodiesagainstdeltaandomicroninmice AT ahmedshahbaz highlythermotolerantsarscov2vaccineelicitsneutralisingantibodiesagainstdeltaandomicroninmice AT khanmohammadsuhail highlythermotolerantsarscov2vaccineelicitsneutralisingantibodiesagainstdeltaandomicroninmice AT malladisameerkumar highlythermotolerantsarscov2vaccineelicitsneutralisingantibodiesagainstdeltaandomicroninmice AT singhrandhir highlythermotolerantsarscov2vaccineelicitsneutralisingantibodiesagainstdeltaandomicroninmice AT pandeysuman highlythermotolerantsarscov2vaccineelicitsneutralisingantibodiesagainstdeltaandomicroninmice AT varadarajanraghavan highlythermotolerantsarscov2vaccineelicitsneutralisingantibodiesagainstdeltaandomicroninmice AT vasanseshadris highlythermotolerantsarscov2vaccineelicitsneutralisingantibodiesagainstdeltaandomicroninmice |